Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | REGN10597 |
| Synonyms | |
| Therapy Description |
REGN10597 is an immunocytokine comprising an anti-PDCD1 (PD-1) antibody fused to IL2Ra-masked IL-2, which potentially inhibits tumor growth (PMID: 39326410). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| REGN10597 | REGN 10597|REGN-10597 | REGN10597 is an immunocytokine comprising an anti-PDCD1 (PD-1) antibody fused to IL2Ra-masked IL-2, which potentially inhibits tumor growth (PMID: 39326410). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06413680 | Phase Ib/II | REGN10597 | A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies | Recruiting | USA | 0 |